Tyra Biosciences, Inc. Overview
Pro stress-test →Tyra Biosciences (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Strategic Profile
Pro stress-test →Tyra has outlined its "dabogratinib 3x3" strategy targeting LG-UTUC, IR NMIBC and achondroplasia, with oral dabogratinib as a potential first-in-class selective FGFR3 inhibitor. CEO Todd Harris narrowed the company's focus to "highest value opportunities" for dabogratinib in three lead areas: low-grade upper tract urothelial carcinoma (UTUC), intermediate-risk non-muscle invasive bladder cancer (NMIBC), and skeletal dysplasias with achondroplasia.
Competitive Landscape
Pro stress-test →Tyra is a precision oncology company integrating bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors, leveraging genomic datasets to address populations with high unmet medical need. Competitors include other FGFR inhibitor developers (Loxo, BridgeBio) and precision oncology platforms in early-stage development.
Industry Context
Tyra Biosciences, Inc. operates in Precision Oncology / Biotechnology.
Key facts
Founded: 2015 · Headquarters: Carlsbad, US · Employees: 60 · Revenue: $0B · Market cap: $1.63B